Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A. reported the results of its 2026 Annual General Meeting held in Marseille on May 21, 2026. All resolutions were voted, with a total of 94 votes cast out of 34,872,293 shares representing 34,921,313 voting rights, corresponding to a 37,136% quorum.
The detailed resolutions, voting results, related documents and an AGM recording will be provided in the 2026 Annual General Meeting section of the company’s website. Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies for cancer, with collaborations including AstraZeneca and Sanofi.
Positive
- None.
Negative
- None.
Key Figures
Shares with voting rights: 34,872,293 shares
Total voting rights: 34,921,313 voting rights
AGM quorum: 37,136%
3 metrics
Shares with voting rights
34,872,293 shares
Shares giving right to voting rights at 2026 AGM
Total voting rights
34,921,313 voting rights
Voting rights referenced for 2026 AGM
AGM quorum
37,136%
Quorum for the 2026 Annual General Meeting
Key Terms
Annual General Meeting, voting rights, clinical-stage biotechnology company, immunotherapies, +2 more
6 terms
Annual General Meeting financial
"announced the voting results of its shareholders at the Annual General Meeting"
voting rights financial
"shares giving right to 34,921,313 voting rights, representing a quorum"
Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.
clinical-stage biotechnology company financial
"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies"
immunotherapies medical
"biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
Universal Registration Document regulatory
"Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
non-small cell lung cancer medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer"
A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.
FAQ
What did Innate Pharma (IPHA) announce in its May 2026 Form 6-K?
Innate Pharma announced the voting results of its 2026 Annual General Meeting. All resolutions were voted, and detailed results, documents, and a recording will be made available in the Annual General Meeting 2026 section of the company’s website.
Where can investors find detailed voting results for Innate Pharma’s 2026 AGM?
Investors can find detailed resolutions, vote counts, and related documents in the Annual General Meeting 2026 section of Innate Pharma’s website. The company also plans to provide an AGM recording there, offering further transparency into the meeting discussions and outcomes.
What kind of company is Innate Pharma (Euronext: IPH; Nasdaq: IPHA)?
Innate Pharma is a global clinical-stage biotechnology company focused on immunotherapies for cancer. It develops next-generation antibody therapeutics and advances assets like IPH4502, lacutamab, and monalizumab, working in collaboration with partners such as AstraZeneca, Sanofi, and leading research institutions.
Which key oncology programs does Innate Pharma highlight in this disclosure?
Innate Pharma highlights IPH4502, a differentiated Nectin-4 antibody-drug conjugate, lacutamab, an anti-KIR3DL2 antibody for T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca in non-small cell lung cancer, as core components of its clinical pipeline.